glp 1 receptor agonists canada GLP-1 Access in Canada: Options, Costs & Clinical Considerations – PlexusDx Targeting GLP-1, GIP & GCG

This article was previously distributed in the August 22, 2023, educational email of the Patient Safety Authority, available at About the Author Patient Safety Authority (patientsafety.pa.gov) is an independent state agency that oversees the Pennsylvania Patient Safety Reporting System (PA-PSRS), the largest database of its kind in the United States.

Despite the science underpinning Saxenda, there remains deep scepticism about treating obesity as a medical condition

Lifestyle-Based Approaches: Structured diet, exercise, and behavioural programmes

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

Although not thought to be directly influenced by obesity, lipoprotein (a) is an independent risk factor for cardiovascular disease that is determined by genetics

Tirzepatide is a GLP-1 receptor agonist too, but it is also a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist